Management of Localized Prostate Cancer: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 344: | Line 344: | ||
** '''<span style="color:#ff0000">Disease factors</span>''' | ** '''<span style="color:#ff0000">Disease factors</span>''' | ||
*** '''PSA density''' has been a consistent '''independent predictor of disease reclassification''' (both cancer volume on biopsy and grade) during surveillance.[https://pubmed.ncbi.nlm.nih.gov/34181465/][https://pubmed.ncbi.nlm.nih.gov/27469419/] | *** '''PSA density''' has been a consistent '''independent predictor of disease reclassification''' (both cancer volume on biopsy and grade) during surveillance.[https://pubmed.ncbi.nlm.nih.gov/34181465/][https://pubmed.ncbi.nlm.nih.gov/27469419/] | ||
***Grade group 2 disease on biopsy pathology[https://pmc.ncbi.nlm.nih.gov/articles/PMC10506469/] | |||
***Cancer present in MRI target[https://pmc.ncbi.nlm.nih.gov/articles/PMC10506469/] | |||
***Bilateral disease[https://pubmed.ncbi.nlm.nih.gov/34181465/] | ***Bilateral disease[https://pubmed.ncbi.nlm.nih.gov/34181465/] | ||
***Percent of positive cores[https://pubmed.ncbi.nlm.nih.gov/32852532/][https://pubmed.ncbi.nlm.nih.gov/25819722/] (not percentage of core involvement) on most recent biopsy | ***Percent of positive cores[https://pubmed.ncbi.nlm.nih.gov/32852532/][https://pubmed.ncbi.nlm.nih.gov/25819722/] (not percentage of core involvement) on most recent biopsy | ||